Romosozumab-osteoporosis drug. A new drug has come to market. Amgen
is the company making this drug. Here are reports of some scientific studies:
New England Journal of Medicine (NEJM), the trial demonstrated that,
compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck. Significant increases were also observed in the first BMD assessment at three months. Moreover, in exploratory analyses, increases observed at the lumbar spine and hip were
significantly greater than those observed with current treatments
FOSAMAX® (alendronate sodium) and FORTEO™/FORSTEO® (teriparatide).
Another study done in 2014 showed:
"All dose levels of romosozumab were associated with significant
increases in bone mineral density at the lumbar spine, including
an increase of 11.3% with the 210-mg monthly dose, as compared
with a decrease of 0.1% with placebo and increases of 4.1% with
alendronate and 7.1% with teriparatide.
Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers
and sustained decreases in a bone-resorption marker. Except for mild,
generally nonrecurring injection-site reactions. Sudy by McClung MR1, Grauer A,
Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY,
Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG.
New England Journal Medicine. Jan 2014
Another study: Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions was published in 2014. Current Osteoporosis Rep.
"The SOST gene, which encodes the protein sclerostin, was identified through genetic linkage analysis of sclerosteosis and van Buchem’s disease (VBD) patients. Sclerostin is a secreted glycoprotein that binds to the Low-density lipoprotein Receptor-related Proteins (LRP) 4, 5, and 6 to inhibit Wnt signaling. Since the initial discovery of sclerostin, much understanding has been gained into the role of this protein in the regulation of skeletal biology. In this article, we discuss the latest findings in the regulation of SOST expression, sclerostin mechanisms of action, and the potential utility of targeting sclerostin in conditions of low bone mass."
This is not the only Osteoporosis medication available but it is a new one and researchers hope that it will avoid some of the drawbacks of other drugs eg. spontaneous fractures after long term use etc.
If you are interested in this drug I urge you to speak with your health care provider. He or she should be able to give you solid advice about whether this might be a good drug for your use ....or not.
If you want to read about other treatments available for Osteopenia or Osteoporosis I suggest that you. End of Romosozumab-osteoporosis drug information.
Drug treatments for bone lossNatural Osteoporosis, Osteopenia treatments